KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accounts Payables (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Accounts Payables for 13 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 23.37% to $3.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.9 million, a 23.37% decrease, with the full-year FY2025 number at $3.9 million, down 23.37% from a year prior.
  • Accounts Payables was $3.9 million for Q4 2025 at Xenon Pharmaceuticals, down from $36.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $36.8 million in Q3 2025 to a low of $3.1 million in Q3 2021.
  • A 5-year average of $12.6 million and a median of $7.8 million in 2021 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: skyrocketed 747.58% in 2023, then crashed 80.48% in 2024.
  • Xenon Pharmaceuticals' Accounts Payables stood at $3.8 million in 2021, then surged by 480.91% to $22.2 million in 2022, then grew by 16.93% to $26.0 million in 2023, then plummeted by 80.48% to $5.1 million in 2024, then fell by 23.37% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Accounts Payables are $3.9 million (Q4 2025), $36.8 million (Q3 2025), and $4.8 million (Q2 2025).